vs

Side-by-side financial comparison of Babcock & Wilcox Enterprises, Inc. (BW) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $113.4M, roughly 1.3× Babcock & Wilcox Enterprises, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 0.6%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-7.2M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -16.9%).

Babcock & Wilcox Enterprises, Inc. is an American energy technology and service provider that is active and has operations in many international markets with its headquarters in Akron, Ohio. Historically, the company is best known for their steam boilers.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

BW vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$113.4M
BW
Growing faster (revenue YoY)
TARS
TARS
+127.8% gap
TARS
128.4%
0.6%
BW
More free cash flow
TARS
TARS
$20.1M more FCF
TARS
$13.0M
$-7.2M
BW
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-16.9%
BW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BW
BW
TARS
TARS
Revenue
$113.4M
$151.7M
Net Profit
$-8.4M
Gross Margin
20.6%
Operating Margin
0.2%
-5.3%
Net Margin
-5.5%
Revenue YoY
0.6%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.11
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BW
BW
TARS
TARS
Q4 25
$113.4M
$151.7M
Q3 25
$149.0M
$118.7M
Q2 25
$144.1M
$102.7M
Q1 25
$181.2M
$78.3M
Q4 24
$112.7M
$66.4M
Q3 24
$152.6M
$48.1M
Q2 24
$151.4M
$40.8M
Q1 24
$164.3M
$27.6M
Net Profit
BW
BW
TARS
TARS
Q4 25
$-8.4M
Q3 25
$35.1M
$-12.6M
Q2 25
$-58.5M
$-20.3M
Q1 25
$-22.0M
$-25.1M
Q4 24
$-63.1M
$-23.1M
Q3 24
$-5.3M
$-23.4M
Q2 24
$25.4M
$-33.3M
Q1 24
$-16.8M
$-35.7M
Gross Margin
BW
BW
TARS
TARS
Q4 25
20.6%
Q3 25
24.9%
Q2 25
30.0%
Q1 25
22.1%
Q4 24
16.7%
Q3 24
23.7%
Q2 24
21.8%
Q1 24
23.6%
Operating Margin
BW
BW
TARS
TARS
Q4 25
0.2%
-5.3%
Q3 25
4.4%
-12.2%
Q2 25
5.6%
-21.6%
Q1 25
3.2%
-33.5%
Q4 24
-8.1%
-36.8%
Q3 24
1.0%
-52.3%
Q2 24
-2.9%
-81.6%
Q1 24
3.5%
-136.5%
Net Margin
BW
BW
TARS
TARS
Q4 25
-5.5%
Q3 25
23.5%
-10.6%
Q2 25
-40.6%
-19.8%
Q1 25
-12.1%
-32.1%
Q4 24
-56.0%
-34.8%
Q3 24
-3.5%
-48.7%
Q2 24
16.8%
-81.6%
Q1 24
-10.2%
-129.4%
EPS (diluted)
BW
BW
TARS
TARS
Q4 25
$0.11
$-0.17
Q3 25
$0.30
$-0.30
Q2 25
$-0.63
$-0.48
Q1 25
$-0.26
$-0.64
Q4 24
$-0.73
$-0.57
Q3 24
$-0.10
$-0.61
Q2 24
$0.24
$-0.88
Q1 24
$-0.23
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BW
BW
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$89.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$-131.5M
$343.4M
Total Assets
$662.9M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BW
BW
TARS
TARS
Q4 25
$89.5M
$417.3M
Q3 25
$25.2M
$401.8M
Q2 25
$23.4M
$381.1M
Q1 25
$23.5M
$407.9M
Q4 24
$26.9M
$291.4M
Q3 24
$30.6M
$317.0M
Q2 24
$95.5M
$323.6M
Q1 24
$43.9M
$298.5M
Total Debt
BW
BW
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
BW
BW
TARS
TARS
Q4 25
$-131.5M
$343.4M
Q3 25
$-232.2M
$335.1M
Q2 25
$-309.2M
$332.6M
Q1 25
$-303.0M
$342.5M
Q4 24
$-283.8M
$224.5M
Q3 24
$-203.7M
$237.5M
Q2 24
$-198.9M
$252.2M
Q1 24
$-223.0M
$275.2M
Total Assets
BW
BW
TARS
TARS
Q4 25
$662.9M
$562.2M
Q3 25
$657.9M
$534.6M
Q2 25
$703.5M
$495.0M
Q1 25
$719.7M
$500.8M
Q4 24
$727.0M
$377.0M
Q3 24
$804.6M
$376.3M
Q2 24
$849.1M
$376.8M
Q1 24
$795.5M
$349.3M
Debt / Equity
BW
BW
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BW
BW
TARS
TARS
Operating Cash FlowLast quarter
$-3.0M
$19.3M
Free Cash FlowOCF − Capex
$-7.2M
$13.0M
FCF MarginFCF / Revenue
-6.3%
8.6%
Capex IntensityCapex / Revenue
3.7%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-85.7M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BW
BW
TARS
TARS
Q4 25
$-3.0M
$19.3M
Q3 25
$-32.1M
$18.3M
Q2 25
$-25.3M
$-29.4M
Q1 25
$-8.5M
$-20.7M
Q4 24
$-22.5M
$-22.2M
Q3 24
$-69.5M
$-8.7M
Q2 24
$-11.8M
$-14.4M
Q1 24
$-14.9M
$-37.8M
Free Cash Flow
BW
BW
TARS
TARS
Q4 25
$-7.2M
$13.0M
Q3 25
$-37.6M
$16.3M
Q2 25
$-28.1M
$-30.4M
Q1 25
$-12.8M
$-21.2M
Q4 24
$-23.6M
$-22.3M
Q3 24
$-71.6M
$-8.9M
Q2 24
$-16.4M
$-15.4M
Q1 24
$-18.3M
$-38.0M
FCF Margin
BW
BW
TARS
TARS
Q4 25
-6.3%
8.6%
Q3 25
-25.3%
13.8%
Q2 25
-19.5%
-29.6%
Q1 25
-7.1%
-27.1%
Q4 24
-20.9%
-33.5%
Q3 24
-46.9%
-18.6%
Q2 24
-10.8%
-37.8%
Q1 24
-11.2%
-137.5%
Capex Intensity
BW
BW
TARS
TARS
Q4 25
3.7%
4.2%
Q3 25
3.7%
1.6%
Q2 25
1.9%
1.0%
Q1 25
2.4%
0.8%
Q4 24
1.0%
0.1%
Q3 24
1.4%
0.6%
Q2 24
3.0%
2.5%
Q1 24
2.1%
0.6%
Cash Conversion
BW
BW
TARS
TARS
Q4 25
Q3 25
-0.92×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.46×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BW
BW

Construction$98.8M87%
Other$14.6M13%

TARS
TARS

Segment breakdown not available.

Related Comparisons